摘要
非马沙坦为一新型血管紧张素Ⅱ受体拮抗药,为氯沙坦的衍生物,其降压作用较氯沙坦强,作用时间较氯沙坦持久。非马沙坦于2010年由韩国食品与药物管理局批准用于治疗高血压。本文从药效学、药动学、临床应用及不良反应等方面对非马沙坦进行了综述。
Fimasartan is a new angiotensin Ⅱ receptor antagonist. It was a derivative of losartan and provided higher potency and longer duration than losartan. Fimasartan was approved for the treatment of hypertension by the Korea Food and Drug Administration in 2010. This article summarized the pharmacodynamics, pharmacokinetics, clinical efficacy and adverse reactions of fimasartan.
出处
《中国新药与临床杂志》
CSCD
北大核心
2017年第9期514-517,共4页
Chinese Journal of New Drugs and Clinical Remedies